Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Innovate Biopharmaceuticals Inc. INNT

Healthcare Biotechnology
"Innovate Biopharmaceuticals Inc is a clinical stage biotechnology company. The company is engaged in developing novel medicines for an autoimmune/ inflammatory disease. It includes drug candidates for celiac disease, NASH, Crohn's, and ulcerative colitis."


NDAQ:INNT - Post by User

Innovate Biopharmaceuticals Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(668)
•••
Post by coolfooldumbguyon Jan 29, 2020 8:53pm
132 Views
Post# 30617170

slow to react to buy this one originally

slow to react to buy this one originallyit's my fault because this month was hectic for me with personal stuff going on,but things are settled down for me now,and will probably add more shares here on weakness,so glta shareholders.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities